Safety and side effects of i.v. immunoglobulin therapy

Clinical and Experimental Rheumatology

Volumn 14, Issue SUPPL. 15, 1996, Pages

  Nydegger, U E ^a,b  

^a Central Laboratory in Bern   (Switzerland)

^b Regionales Blutspendezentrum SRK   (Switzerland)

Author keywords

autoimmune diseases; complement; immunoglobulin G; plasma derivatives; therapy

Indexed keywords

IMMUNOGLOBULIN;

ADVERSE DRUG REACTION; AUTOIMMUNITY; CONFERENCE PAPER; DRUG SAFETY; DRUG THERAPY; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; THERAPY;

AGED; ANAPHYLAXIS; BLOOD VISCOSITY; CHILD, PRESCHOOL; FEMALE; FRAIL ELDERLY; HEMOLYSIS; HEPATITIS C; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY DISEASES; MALE; MENINGITIS, ASEPTIC;

EID: 0029777485     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. BARANDUN S, MORELL A, SKVARIL F: Clinical experiences with immunoglobulin for intravenous use. In AL VING BM, FINLAYSON J (Eds.): Immunoglobulins: Characteristics and Uses of Intravenous Preparations, US Health Human Services (FDA) 80-9005, 1980; 31-5.
2. TOUNGOUZ M, DENYS CH, DE GROOTE D et al.: In vitro inhibition of tumour necrosis factor-α and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89; 698-703.
3. GREENBAUM BH: Differences in immunoglobulin preparations for intravenous use: a comparison of six products. Am J Ped Hematol Oncol 1990; 12: 490-6.
4. SCHIAVOTTO C, RUGGERI M, RODEGHIERO F: Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78: (Suppl. 2): 35-40.
5. VAN DER MECHÉ FGA, SCHMITZ PIM, and the DUTCH GUILLAIN-BARRÉ STUDY GROUP: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.
6. TAKEY S, ARORA YK, WALKER SM: Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91: 602-7.
7. SCHIFFERLI J, LESKI M, FAVRE H, IMBACH P, NYDEGGER U, DAVIES K: High-dose intravenous IgG treatment and renal function. Lancet 1991; 337: 457-8.
8. TAN E, HAJINAZARIAN M, BAY W et al.: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-9.
9. SOMER T: Rheology of paraproteinemias and the plasma hyperviscosity syndrome. Baillière Clin Haematol 1987; 1: 695-723.
10. REINHART WH, BERCHTOLD PE: Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-4.
11. DALAKAS MC: High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.
12. SEKUL EA, CUPLER EJ, DALAKAS MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-62.
13. BUCHS JP, NYDEGGER UE: Quantitation of anti-A and anti-B IgG antibodies in therapeutic i.v. immunoglobulin by indirect ELISA. Transfusion Sci 1990; 11: 113-21.
14. OKUBO S, ISHIDA T, YASUNGA K: Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody. Transfusion 1990; 30: 436-8.
15. VON ALLMEN E. RIEBEN R, NYDEGGER UE: Development of a C1q-ABO-ELISA to measure C1q binding by human anti-A alloantibodies. J Immunol Methods 1994; 171: 85-92.
16. LEVER AML, WEBSTER ADB, BROWN D, THOMAS HC: Non-A, non-B hepatitis occurring in a gammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984; ii: 1062-4.
17. IMBACH P, PERRET BA, BABINGTON R et al.: Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang 1991; 61: 240-3.
18. GARDULF A, ANDERSEN V. BJORKANDER J et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365-9.
19. WELLS MA, WITTEK AE, EPSTEIN JS et al.: Inactivation and partition of human T-cell lymphotrophic virus type III, during ethanol fractionation of plasma. Transfusion 1986; 26: 210-3.
20. KEMPF C, JENTSCH P, POIRIER B et al.: Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991; 31: 423-7.